[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity
Phio Pharmaceuticals (PHIO) director Curtis Lockshin reported an insider grant and updated holdings on Form 4. On 09/11/2025 he was granted 16,200 shares (reported as shares underlying a restricted stock unit) that will vest on the first annual anniversary of the grant; the grant was recorded at a $0 price. After the reported transaction, the filing shows Mr. Lockshin beneficially owns 18,555 shares, which includes shares underlying unvested restricted stock units. The filing notes the reported totals were adjusted for prior reverse stock splits and the Form 4 was signed on 09/15/2025 by an attorney-in-fact.
Curtis Lockshin, amministratore di Phio Pharmaceuticals (PHIO), ha riportato un grant interno e aggiornato le sue partecipazioni nel Form 4. Il 11/09/2025 gli è stato concesso un numero di 16.200 azioni (riportate come azioni sottostanti a una RSU) che matureranno al primo anniversario annuale del conferimento; l'assegnazione è stata registrata a un prezzo di $0. Dopo la transazione riportata, il modulo indica che il signor Lockshin detiene beneficiariamente 18.555 azioni, che includono azioni sottostanti a RSU non vestite. Il documento segnala che i totali riportati sono stati rettificati per i precedenti reverse stock split e il Form 4 è stato firmato il 15/09/2025 da un procuratore con procura.
El director de Phio Pharmaceuticals (PHIO), Curtis Lockshin, reportó una adjudicación interna y actualizó sus participaciones en el Formulario 4. El 11/09/2025 se le otorgaron 16.200 acciones (registradas como acciones subyacentes a una RSU) que vencerán en el primer aniversario del otorgamiento; la adjudicación se registró a un precio de $0. Tras la operación, el formulario indica que el Sr. Lockshin posee en beneficio 18.555 acciones, incluidas las acciones subyacentes a RSUs no vestidas. El documento señala que los totales reportados fueron ajustados por splits reversos de acciones previos y que el Formulario 4 fue firmado el 15/09/2025 por un apoderado.
Phio Pharmaceuticals(PHIO)의 이사 Curtis Lockshin은 Form 4에서 내부자 부여와 보유 현황 업데이트를 보고했습니다. 2025년 9월 11일에 그는 16,200주를 부여받았으며(RSU의 기초 주식으로 보고됨) 이는 부여의 첫 연차일에 vest가 됩니다; 부여는 $0의 가격으로 기록되었습니다. 보고된 거래 후, 서류상 로크친 씨는 미 vest RSU를 기초로 한 주를 포함하여 총 18,555주를 실질적으로 소유하고 있습니다. 서류는 보고된 합계가 이전의 역분할로 조정되었고 Form 4는 2025년 9월 15일 대리인에 의해 서명되었다고 명시합니다.
Un administrateur de Phio Pharmaceuticals (PHIO), Curtis Lockshin, a signalé une attribution interne et une mise à jour de ses participations sur le Formulaire 4. Le 11/09/2025, il a reçu 16 200 actions (signalées comme actions sous-jacentes à une RSU) qui vestent lors du premier anniversaire annuel de l'attribution; l'attribution a été enregistrée à un prix de 0 $. Après l'opération, le formulaire indique que M. Lockshin possède bénéficiairement 18 555 actions, y compris les actions sous-jacentes à des RSU non acquises. Le document note que les totaux signalés ont été ajustés pour des divisions inverses antérieures et que le Form 4 a été signé le 15/09/2025 par un mandataire.
Der Direktor von Phio Pharmaceuticals (PHIO), Curtis Lockshin, hat einen Insider-Zuwendung gemeldet und seine Beteiligungen im Form 4 aktualisiert. Am 11.09.2025 erhielt er 16.200 Aktien (als Aktien unterliegend einer RSU gemeldet), die am ersten jährlichen Jahrestag der Zuwendung vesten; die Zuweisung wurde zu einem Preis von 0 $ registriert. Nach der gemeldeten Transaktion besitzt Herr Lockshin begünstigt 18.555 Aktien, einschließlich solcher, die RSUs unterliegen, die noch vesten. Im Dokument wird darauf hingewiesen, dass die gemeldeten Gesamtsummen aufgrund vorheriger Reverse-Splits angepasst wurden und das Form 4 am 15.09.2025 von einem Vollmachtsträger unterschrieben wurde.
أبلغ مدير Phio Pharmaceuticals (PHIO) كيرتس لوكشين عن منح داخلي وتحديث الملكية في النموذج 4. في 11/09/2025 مُنِح 16,200 سهماً (مُسجَّلة كأوراق مالية تحت RSU مقيدة) ستت vest في أول ذكرى سنوية للمنحة؛ تم تسجيل المنحة بسعر 0 دولار. بعد المعاملة المبلغ عنها، يظهر الملف أن السيد لوكشين يمتلك فائدة بنحو 18,555 سهماً، بما في ذلك الأسهم الأساسية لـ RSUs غير vest. وتلاحظ الوثيقة أن الإجماليات المبلغ عنها قد تم تعديلها بسبب عمليات تقسيم عكسي سابقة وأن النموذج 4 تم التوقيع عليه في 15/09/2025 من قبل وكيل قانوني.
Phio Pharmaceuticals（PHIO）董事Curtis Lockshin在Form 4上报告了内部人授予并更新了持股。 2025年9月11日，他获授16,200股（记为受限股票单位RSU所对应的股票），该股份将在授予后的第一个年度周年日 vest；该授予的记录价格为0美元。交易后，备案显示Lockshin先生实际拥有18,555股，其中包括未 vest的RSU所涵盖的股份。备案指出，所报告的总数已针对先前的反向股票拆分进行了调整，且Form 4于2025年9月15日由一名代理律师签署。
- Director grant documented with clear vesting terms (shares vest on the first annual anniversary)
- Beneficial ownership disclosed: the filing shows 18,555 shares beneficially owned after the transaction
- Disclosure adjusted for corporate actions (reported numbers reflect prior reverse stock splits)
- None.
Insights
TL;DR: A director received time‑based RSUs, increasing reported beneficial ownership modestly; disclosure is routine and compliance-oriented.
The Form 4 documents a standard equity grant to a director: 16,200 shares underlying a restricted stock unit award vesting on the first anniversary and recorded at $0, consistent with compensation grants rather than open‑market purchases. Beneficial ownership after the grant is 18,555 shares, and the filing discloses adjustments for prior reverse splits. This is a governance/compliance disclosure showing alignment of the director with equity incentives; there are no derivative exercises, sales, or cash purchases reported.
TL;DR: The entry reflects a non‑cash RSU award to a director; immaterial to capital structure absent further grants or exercises.
The transaction code 'A' and explanatory notes indicate shares were granted as restricted stock units, vesting after one year. The reported $0 price confirms the award treatment rather than a paid acquisition. The filing correctly adjusts numbers for prior reverse stock splits and is executed via power of attorney. From an equity‑compensation perspective this is a routine director award; no immediate dilutive issuance to public markets is documented here.
Curtis Lockshin, amministratore di Phio Pharmaceuticals (PHIO), ha riportato un grant interno e aggiornato le sue partecipazioni nel Form 4. Il 11/09/2025 gli è stato concesso un numero di 16.200 azioni (riportate come azioni sottostanti a una RSU) che matureranno al primo anniversario annuale del conferimento; l'assegnazione è stata registrata a un prezzo di $0. Dopo la transazione riportata, il modulo indica che il signor Lockshin detiene beneficiariamente 18.555 azioni, che includono azioni sottostanti a RSU non vestite. Il documento segnala che i totali riportati sono stati rettificati per i precedenti reverse stock split e il Form 4 è stato firmato il 15/09/2025 da un procuratore con procura.
El director de Phio Pharmaceuticals (PHIO), Curtis Lockshin, reportó una adjudicación interna y actualizó sus participaciones en el Formulario 4. El 11/09/2025 se le otorgaron 16.200 acciones (registradas como acciones subyacentes a una RSU) que vencerán en el primer aniversario del otorgamiento; la adjudicación se registró a un precio de $0. Tras la operación, el formulario indica que el Sr. Lockshin posee en beneficio 18.555 acciones, incluidas las acciones subyacentes a RSUs no vestidas. El documento señala que los totales reportados fueron ajustados por splits reversos de acciones previos y que el Formulario 4 fue firmado el 15/09/2025 por un apoderado.
Phio Pharmaceuticals(PHIO)의 이사 Curtis Lockshin은 Form 4에서 내부자 부여와 보유 현황 업데이트를 보고했습니다. 2025년 9월 11일에 그는 16,200주를 부여받았으며(RSU의 기초 주식으로 보고됨) 이는 부여의 첫 연차일에 vest가 됩니다; 부여는 $0의 가격으로 기록되었습니다. 보고된 거래 후, 서류상 로크친 씨는 미 vest RSU를 기초로 한 주를 포함하여 총 18,555주를 실질적으로 소유하고 있습니다. 서류는 보고된 합계가 이전의 역분할로 조정되었고 Form 4는 2025년 9월 15일 대리인에 의해 서명되었다고 명시합니다.
Un administrateur de Phio Pharmaceuticals (PHIO), Curtis Lockshin, a signalé une attribution interne et une mise à jour de ses participations sur le Formulaire 4. Le 11/09/2025, il a reçu 16 200 actions (signalées comme actions sous-jacentes à une RSU) qui vestent lors du premier anniversaire annuel de l'attribution; l'attribution a été enregistrée à un prix de 0 $. Après l'opération, le formulaire indique que M. Lockshin possède bénéficiairement 18 555 actions, y compris les actions sous-jacentes à des RSU non acquises. Le document note que les totaux signalés ont été ajustés pour des divisions inverses antérieures et que le Form 4 a été signé le 15/09/2025 par un mandataire.
Der Direktor von Phio Pharmaceuticals (PHIO), Curtis Lockshin, hat einen Insider-Zuwendung gemeldet und seine Beteiligungen im Form 4 aktualisiert. Am 11.09.2025 erhielt er 16.200 Aktien (als Aktien unterliegend einer RSU gemeldet), die am ersten jährlichen Jahrestag der Zuwendung vesten; die Zuweisung wurde zu einem Preis von 0 $ registriert. Nach der gemeldeten Transaktion besitzt Herr Lockshin begünstigt 18.555 Aktien, einschließlich solcher, die RSUs unterliegen, die noch vesten. Im Dokument wird darauf hingewiesen, dass die gemeldeten Gesamtsummen aufgrund vorheriger Reverse-Splits angepasst wurden und das Form 4 am 15.09.2025 von einem Vollmachtsträger unterschrieben wurde.
FAQ
What transaction did Curtis Lockshin report on Form 4 for PHIO?
How many PHIO shares does the reporting person beneficially own after the transaction?
When do the restricted stock units vest?
Was the Form 4 adjusted for corporate actions like reverse splits?
Who signed the Form 4 and when was it filed?
